CHICAGO -- Patients with advanced prostate cancer treated with enzalutamide (Xtandi) had a significantly greater decline in ...

Less is more in the case of this cancer treatment. The most common form of cancer among men in the US, after skin cancer, ...

Long-term follow-up consistent with earlier report, a hint of benefit in high-grade diseas ...

UVA Health Prince William Medical Center has begun offering Aquablation therapy, an advanced AI-powered treatment for benign ...

TEM is integrating externally developed AI pathology into its ecosystem to improve risk prediction and personalize prostate ...

Researchers with the James P. Allison Institute at The University of Texas MD Anderson Cancer Center have discovered a new ...

Approximately one in eight American men will be diagnosed with prostate cancer during their lifetime. For most of them, if ...

the hospital, the patient had been suffering from prolonged difficulty in urination along with repeated episodes of urinary retention, which had considerably impacted his quality of life ...

Prostate-specific antigen (PSA) blood testing likely reduces the risk of death from prostate cancer, found a new review ...

A treatment option for prostate cancer patients is now available in the Midstate. The UPMC Hillman Cancer Center in Harrisburg can now provide HDR, or high-dose rate prostate ...

Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

Editor's note: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine.When I learned that ...